Compare IDEXX Laboratories, Inc. (IDXX) vs Rivian Automotive, Inc. (RIVN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Rivian Automotive, Inc. — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Rivian Automotive, Inc. trades at $13.96 (market cap $20.75B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 26,144,654). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Rivian Automotive, Inc. for 61 Days on average.
| IDXX | RIVN | |
|---|---|---|
Market Cap | $40.43B | $20.75B |
Volume | 692,164 | 26,144,654 |
Sector | Health | Consumer Cyclical |
52-Week High | $766.68 | $22.45 |
52-Week Low | $504.70 | $12.50 |
Typical Hold Time | 46 Days | 61 Days |
Enterprise Value | $41.32B | $20.79B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
Rivian Automotive (RIVN) trades at $14.33, down slightly by 0.07% on the day, amid a bearish technical outlook but with improving operational trends. The company reported record Q3 2026 deliveries of 19,248 vehicles, beating estimates and reaffirming full-year guidance, though the stock dipped as investors hoped for a forecast upgrade. Financially, revenue growth continues but losses persist, with a net income margin of -54.95% in 2025, while cash burn has moderated from prior years.
The outlook remains challenged by high cash burn and competitive pressures, but cost controls and R2 SUV ramp-up offer a path to profitability. Analyst consensus is cautiously optimistic with a $16.89 price target, though risks include execution delays and EV market volatility. The stock presents a high-risk, high-reward opportunity for investors betting on Rivian's scaling and autonomy initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →
